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Abstract
SmyD2 belongs to a new class of chromatin regulators that control gene expression in heart development and
tumorigenesis. Besides methylation of histone H3 K4, SmyD2 can methylate non-histone targets including p53 and the
retinoblastoma tumor suppressor. The methyltransferase activity of SmyD proteins has been proposed to be regulated by
autoinhibition via the intra- and interdomain bending of the conserved C-terminal domain (CTD). However, there has been
no direct evidence of a conformational change in the CTD. Here, we report two crystal structures of SmyD2 bound either to
the cofactor product S-adenosylhomocysteine or to the inhibitor sinefungin. SmyD2 has a two-lobed structure with the
active site located at the bottom of a deep crevice formed between the CTD and the catalytic domain. By extensive
engagement with the methyltransferase domain, the CTD stabilizes the autoinhibited conformation of SmyD2 and restricts
access to the catalytic site. Unexpectedly, despite that the two SmyD2 structures are highly superimposable, significant
differences are observed in the first two helices of the CTDs: the two helices bend outwards and move away from the
catalytic domain to generate a less closed conformation in the sinefungin-bound structure. Although the overall fold of the
individual domains is structurally conserved among SmyD proteins, SmyD2 appear to be a conformational ‘‘intermediate’’
between a close form of SmyD3 and an open form of SmyD1. In addition, the structures reveal that the CTD is structurally
similar to tetratricopeptide repeats (TPR), a motif through which many cochaperones bind to the heat shock protein Hsp90.
Our results thus provide the first evidence for the intradomain flexibility of the TPR-like CTD, which may be important for the
activation of SmyD proteins by Hsp90.
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Introduction
Covalent histone modifications represent an important regula-
tory mechanism controlling gene transcription, essential for
normal growth and development [1]. Disrupting the balance of
histone modifications can lead to the altered expression of genes
involved in tumorigenesis including proto-oncogenes and cell cycle
regulators [2]; however, little is known about how the enzymes
that control histone modifications are regulated posttranslational-
ly. Members of the SET and MYND domain containing (SmyD)
family of proteins possess histone lysine methyltransferase capacity
and have been shown to be involved in the transcriptional control
of cell differentiation and cell proliferation [2,3,4,5,6]. The SmyD
protein family consists of five proteins (SmyD1–5) that share about
30% sequence identity with each other and are grouped based on
the presence of two conserved domains (MYND and SET
domains) [4]. The MYND domain is a zinc finger motif that is
involved in protein–protein interaction [7]. The SET domain is an
evolutionarily conserved motif consisting of about 130 amino acids
that is responsible for adding methyl groups to lysine residues
of proteins using S-adenosylmethionine (AdoMet) as a donor
substrate.
Evidence for a critical role of SmyD proteins during organ
development was first shown by the constitutive knockout of
SmyD1, resulting in early embryonic lethality due to disruption of
cardiac differentiation and morphogenesis [3]. Subsequent reports
have further indicated that SmyD proteins are indeed critical
regulators of cardiac as well as skeletal muscle development
[5,8,9,10,11]. Despite being highly expressed in heart and brain, a
specific functional role for SmyD2 in these organs has not been
well characterized [2,10]. Overexpression of SmyD2 has been
shown to cause changes in expression of genes associated with
chromatin remodeling, cell cycle, and transcription regulation,
indicating that this protein may function as a transcriptional
regulator by methylating H3 K4 and participates in cell cycle
regulation and cell growth [4]. Interest in SmyD2 has grown
significantly because of recent reports indicating that SmyD2
repress transcriptional p53 activity by lysine methylation (Lys370),
exerting an oncogenic and drug resistance action through
inhibition of p53-mediated cell death pathways [12]. In addition
to p53 methylation, a new study showed that the retinoblastoma
tumor suppressor (RB), a central cell cycle regulator and tumor
suppressor, can also be methylated by SmyD2 at lysine 860, which
regulates the RB activity during cell cycle progression, cellular
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agreement with these observations, SmyD2 recently has been
shown to act as a cancer-promoting gene through activation or
overexpression in esophageal squamous cell carcinoma [14].
These studies thus support a role for SmyD2 in the regulation of
proliferation and in tumor progression, which underscores the
importance of elucidating the regulation of SmyD2 activity.
The molecular chaperone Hsp90 plays an important role in the
folding, activation, intracellular transport, and assembly of a broad
range of client proteins, specifically chaperoning molecules
involved in signal transduction and cell cycle regulation [15].
Mounting evidence showed that Hsp90 is also involved in
transcriptional regulation and epigenetic inheritance by interact-
ing with epigenetic proteins that function in chromatin remodeling
and histone modifications [16,17]. Based on the ability of Hsp90
to stimulate the activity of SmyD proteins, recent studies have
characterized SmyD proteins as new clients of Hsp90 [4,17];
however, the critical questions regarding how Hsp90 activates
SmyD proteins remain poorly understood. Previous studies
suggested that the methyltransferase activity of SmyD proteins is
suppressed by an autoinhibited conformation maintained by the
CTD, a helix bundle C-terminal to the catalytic SET domain that
is conserved and unique in SmyD proteins [18,19]. It has been
proposed that the intra- and interdomain bending of the CTD
may be central for the activation of SmyD proteins by Hsp90 [19].
In this paper, we report two crystal structures of full-length SmyD2
in complex with the methyltransferase inhibitor sinefungin (SFG)
and the cofactor product S-adenosylhomocysteine (AdoHcy). Our
studies demonstrate for the first time the intradomain flexibility of
the CTD and reveal the structural resemblance of the auto-
inhibitory CTD to tetratricopeptide repeat (TPR) motif, which
suggest a mechanism for the Hsp90-mediated activation of SmyD
proteins. Our findings therefore contribute to the understanding of
the mechanism that regulates the activity of SmyD proteins in
early heart development and tumorigenesis.
Results and Discussion
SmyD2 structure with the TPR-like CTD
Two crystal structures of full-length SmyD2 in complex with the
cofactor product AdoHcy and the methyltransferase inhibitor
sinefungin have been determined at 2.1 A ˚ and 1.8 A ˚ by zinc
single-wavelength anomalous dispersion (Table 1). Similar to
SmyD1 and SmyD3 [18,19], SmyD2 has a multidomain structure
that folds into two lobes with overall dimensions of approximately
65 A ˚640 A ˚655 A ˚ (Figure 1). Although the overall fold of their
individual domains is structurally conserved, the SmyD family
proteins differ dramatically in the relative orientation between the
N- and C-terminal lobes. Detailed description of the structural
differences will be addressed later in the article. The N-terminal
lobe (residues 3–279) is composed of four domains: the catalytic
SET domain, located in the middle of this lobe, is surrounded by
the zinc finger MYND, insertion SET-I, and post-SET domains.
Immediately C-terminal to the post-SET domain, the polypeptide
forms a large domain of about 150 residues that constitutes the C-
terminal lobe (residues 280–432). This domain is conserved in the
SmyD proteins and was referred to as the CTD in our previous
studies [18]. The CTD is composed of seven antiparallel a-helices
(aH–aN) rotated relative to one another by an approximately 25u.
This topology creates a right-handed superhelical structure
generating a concave surface on one side with a convex surface
on the other. Despite the absence of any significant sequence
similarities, the overall fold of the CTD is reminiscent of that of
TPR repeats that adopt a helix-turn-helix structure. Given that the
TPR repeats mediate specific protein–protein interactions and the
assembly of multiprotein complexes, the structural similarity of the
CTD and the TPR repeats suggests a function for the CTD as a
protein-protein interaction module.
The architecture of the catalytic SET domain of SmyD2 is
essentially similar to that of SmyD1 and SmyD3 [18,19], which
features a ‘‘split’’ domain defined by two separated segments, the
S-sequence (residues 3–49) and the core SET domain (residues
183–246). Despite the split in the primary structure, the SET
domain in SmyD2 has the similar overall fold to other SET
domain containing proteins, characterized by one central 310 helix
(310-3) and 10 b-strands (b1–b5 and b8–b12) that are arranged into
Table 1. Crystallographic data and refinement statistics.
Sinefungin AdoHcy
Space group P212121 P212121
Cell parameters (A ˚)
a 57.5 57.9
b 75.1 75.0
c 112.5 113.4
Wavelength (A ˚) 0.97872 1.28215
Resolution (A ˚) 30.0-1.8 30.0-2.03
Rmerge
a 0.083 (0.503)
b 0.102 (0.512)
Redundancy 6.0 (5.8) 11.3 (10.3)
Unique reflections 45863 32539
Completeness (%) 99.7 (99.5) 99.9 (99.1)
ÆI/sæ 8.9 (2.8) 9.5 (4.6)
Refinement
Resolution (A ˚) 30-1.8 30-2.03
Molecules/AU 1 1
Rwork
c 0.186 (0.224) 0.173 (0.193)
Rfree
d 0.208 (0.275) 0.215 (0.226)
RMSD
Bond lengths (A ˚) 0.010 0.010
Bond angels (u) 1.0 1.1
No. of atoms
Protein 3465 3453
Sinefungin/AdoHcy 27 26
Water 429 392
Zinc 3 3
B-factor (A ˚2)
Protein 25.8 29.0
Sinefungin/AdoHcy 12.8 19.7
Water 33.4 35.5
Ramachandran plot
Preferred regions (%) 97.12 96.92
Allowed regions (%) 2.88 3.08
Outliers (%) 0.0 0.0
aRmerge=S|I2ÆIæ|/SI, where I is the observed intensity and ÆIæ is the averaged
intensity of multiple observations of symmetry-related reflections.
bNumbers in parentheses refer to the highest resolution shell.
cRwork=S|Fo2Fc|/S|Fo|, where Fo is the observed structure factor, Fc is the
calculated struture factor.
dRfree was calculated using a subset (5%) of the reflection not used in the
refinement.
doi:10.1371/journal.pone.0021640.t001
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the loop connecting 310-3 and b10 that contributes conserved
catalytic residues and functions to bind the cofactor at the bottom
of the cofactor binding site, and the strand b8 and the loop
following b10 that form a narrow cleft predicted to accommodate
substrate H3 peptide (Figure 2). However, the SET domain alone
is not sufficient for lysine methylation and it requires the
cooperation with three other domains, including the N- and C-
terminal flanking domains (pre-SET and post-SET) as well as the
insertion SET-I domain [20,21,22]. The latter three domains are
not conserved with highly variable structures in the known SET
proteins but they occupy similar positions and play similar roles
in these enzymes. Interestingly, SmyD2 does not contain the
pre-SET domain, though this domain is required by other SET
Figure 1. Ribbon diagram of the SmyD2 structures. (A) Side view (left) and top view (right) of the binary structure of SmyD2–sinefungin. (B)
The structure of SmyD2–AdoHcy. Secondary structures of SmyD2, a-helices, 310-helices, and b-strands are labeled and numbered according to their
position in the sequence. The S-sequence, MYND, SET-I, core SET, post-SET, and CTD are depicted in light green, blue, pink, green, cyan, and red,
respectively, while sinefungin and AdoHcy are represented by balls-and-sticks and zinc ions are denoted by purple spheres. (C) Superposition of two
SmyD2 structures in complex with sinefungin (red) and AdoHcy (cyan) based on their N-lobes. The maximum distance between the equivalent
regions in the outer edge of their C-lobes is indicated. The intradomain motion is indicated by the straight arrow and the approximate rotation angle
is given. (D) Ribbon diagram of the structure of SmyD1 and (E) SmyD3 with the domains colored the same as above.
doi:10.1371/journal.pone.0021640.g001
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histone binding site [21].
Both post-SET and SET-I domains are engaged in cofactor and
substrate binding [20]. The post-SET domain, which is immedi-
ately downstream of the SET domain, is a small cysteine-rich
region consisting of three short a-helices (aE, aF, and aG) that are
organized around a single zinc ion (Figure 1). The zinc ion is
coordinated by four highly conserved cysteine residues: Cys262,
Cys264, and Cys267 from the post-SET domain and Cys209 from
the SET domain. This zinc ion thus appears to be important for
the folding of the post-SET domain and also tethers this domain to
the SET domain. As a result of this tethering, the post-SET
domain lies close to the active site, with the loop connecting aE
and aF placed near the cofactor, and the C-terminal end of helix
aE positioned to participate in the formation of the substrate
binding cleft. Similar to other SmyD proteins [18,19], SmyD2 has
a large SET-I domain consisting of a helix bundle (aB, 310-1,3 10-2,
aC, and aD) of as many as 84 residues, together with the MYND
inserted between the SET strands b5 and b8 (Figure 1). The
equivalent region in Set7/9 or Dim-5, however, contains only one
or two small helices of 15–20 residues [23,24]. In contrast to the
MYND, the SET-I domain packs against the opposite face of the
b-sheet containing b4, b10, and b11, contributing to the cofactor
and substrate binding. Specifically, the last two helices (aC and
aD) of the SET-I domain might be important for the recognition
of the H3 N-terminal residues (Figure 2), while the loop between
the 310-1 and 310-2 helices makes extensive contacts with the
cofactor.
MYND mediates protein–protein interactions by binding to a
proline-rich sequence [7]. It has been demonstrated that the
MYND present in SmyD2 interacts with proteins containing the
PXLXP motif, such as EBP41L3, a functional suppressor of
epithelial ovarian cancers [4]. As shown in Figure 1A, the MYND
consists of one kinked a helix (aA) and two antiparallel b-strands
(b6, b7) that are organized around 2 zinc ions. Despite that it
forms direct contacts with the catalytic SET domain, the MYND
does not contribute residues to cofactor binding. In addition, this
domain is more than 10 A ˚ away from the putative substrate-
binding pocket and may not be directly involved in substrate
recognition (Figure 2). These observations are in agreement with
previous findings that the MYND is dispensable for the histone
methylation activity of SmyD2 [4], implicating that the MYND
may primarily function as a protein–protein interaction module
and cooperate SmyD2 with other proteins to regulate tumor
proliferation and progression. The structure of the MYND of
SmyD2 is very similar to that of SmyD1, SmyD3 and AML1/
ETO [7,18,19], with the following pairwise RMSDs for Ca atoms
over 40 residues: 0.48 A ˚, 0.53 A ˚, and 0.81 A ˚, respectively.
Superposition of the MYNDs of SmyD2 and AML1/ETO, which
was solved in complex with a peptide containing the ‘‘PPPLI’’
motif [7], reveals that the proline-rich peptide is located in a
shallow, fully exposed surface groove that is readily accessible by
other proteins. One side of the groove is formed by a loop
connecting b6 and b7, and the other side by the residues from the
N-terminal half of helix aA. Three highly conserved residues
(Trp80, Gln76, and Tyr70 in SmyD2) critical for AML1/ETO
binding to the peptide are highly superimposable in the two
structures. The high structural similarity suggests a similar mode
of recognition of proline-rich sequences shared by these two
MYNDs.
Active site characterized by a spacious target lysine
access channel
We have determined two complex structures of SmyD2 bound
either to the cofactor product AdoHcy or to a potent
methyltransferase inhibitor sinefungin. The two structures are
remarkably similar to each other in terms of cofactor binding.
Therefore, the following discussion on the interaction between
SmyD2 and the cofactor will be solely focused on the SFG-bound
SmyD2 structure. Similar to that in other SmyD proteins [18,19],
the L-shaped sinefungin binds in a deep surface pocket formed by
the SET-I, SET and post-SET domains (Fig. 2A). In particular,
the adenine moiety of sinefungin is sandwiched between the benzyl
ring of Phe260 and the aliphatic side chain of Lys17, with its
purine N6 and N7 atoms hydrogen-bonding to the backbone
carbonyl and amide groups of His207, respectively. The ribose
hydroxyls of the cofactor make three hydrogen bonds with the side
chains of His137 and Glu135 and the carbonyl oxygen of Tyr258.
At the opposite end of sinefungin, the positively charged a-amino
group is recognized by a trigonal array of hydrogen bonds with the
Figure 2. Cofactor binding pocket and substrate binding site. (A) Interaction between SmyD2 and sinefungin. SmyD2 residues are
represented by balls-and-sticks with their carbon atoms colored according to the scheme in Figure 1. Sinefungin is depicted by balls-and-sticks
overlaid with 2Fo2Fc omit map calculated at 1.8 A ˚ and contoured at 2.5 s. Hydrogen bonds are illustrated as red broken lines. (B) Ribbon diagram of
the putative substrate binding site, illustrating the interaction between SmyD2 and the modeled H3 peptide. The H3 peptide (1–10) from the Set7/9
structure (PDB code 1O9S) is displayed as balls-and-sticks with carbon atoms colored yellow. (C) Superposition of the target lysine-access channelso f
SmyD2, SmyD1, and SmyD3. The oval-shaped channel in SmyD2 is depicted by molecular surface. Residues in SmyD2 are represented by balls-and-
sticks, while residues in SmyD1 and SmyD3 are displayed as sticks in purple and orange, respectively. Target lysine (H3K4) is colored in yellow.
doi:10.1371/journal.pone.0021640.g002
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Od of Asn206, while the carboxylate moiety forms salt-bridge
interactions with the guanidinium group of Arg19. The latter
electrostatic interactions are present in most SET proteins
including SmyD1 but are replaced by a hydrogen bond to a
tyrosine residue in SmyD3, which represents an unusual variation
[19]. In the middle of sinefungin, the C–NH3 amine group, which
is in place of the S–CH3 sulfonium of AdoMet, engages in two
hydrogen bonds with the backbone oxygen of Ala203 and the
amide Od of Asn182. The similar interactions are expected in the
case of AdoMet, which might contribute to enzymatic function by
destabilizing the active methyl group. Collectively, the overall
cofactor-binding mode of SmyD2 is structurally conserved with
SmyD1 and SmyD3 and other SET enzymes and serves to orient
the methyl group of AdoMet into the methyltransfer pore during
catalysis.
Although the SmyD2 structures were solved without substrate,
superposition of SmyD2 with histone H3-bound Set7/9, a H3
lysine 4 methyltransferase, offers insights into substrate recogni-
tion. As shown in Figure 2B, the modeled H3 peptide binds in a
deep, rectangle-shaped cleft formed by the SET, post-SET and
SET-I domains. In the cleft, the b8 strand and the loop preceding
the post-SET domain are predicted to interact with substrate
histone in a hybrid b-sheet-binding mode as shown in other SET
proteins [20]. Lys4 of the peptide is at the center of this b-sheet
interaction, which firmly deposits its side chain into the target
lysine access channel that leads to sinefungin that binds on the
opposite face of the SET domain. Comparison of SmyD2, SmyD1,
and SmyD3 reveals that the structures of the lysine access channel
of these enzymes are similar to each other with a large oval-shaped
opening (Figure 2C). The residues in SmyD2 involved in the
formation of the channel including Tyr240, Tyr258, Val202,
Val215, and Thr238, are highly structurally aligned with the
equivalent residues in SmyD1 and SmyD3, except for Phe184.
The spacious lysine access channel is a characteristic feature of
SmyD proteins, which is mainly attributed to the replacement of
some bulky aromatic residues in Set7/9 or other SET proteins by
small hydrophobic ones in SmyD proteins [18,19]. In SmyD1,
substitution of Val214 by tyrosine, a mutation that would create a
tighter active site pocket, results in a significant increase in H3
binding and also enhances SmyD1 methylation, indicating that
this large channel made SmyD1 unable to effectively interact with
the target lysine during methyl transfer, affecting its enzymatic
activity [18].
A unique feature of SmyD proteins is the presence of the
conserved CTD, which is located near the substrate binding cleft
and together with the SET domain forms a deep canyon that
spans the entire molecule [18,19]. Similar to SmyD3, the putative
substrate binding site of SmyD2 is located at the bottom of the 15-
A ˚-deep crevice, with the CTD acting like a lid and partially
covering the active site pocket (Figure 1). However, because of the
location of the CTD, severe steric clashes are observed between
the C-terminus of the peptide and the CTD inner surface in the
SmyD2–H3 model (Figure 2B). The steric hindrance of the CTD
suggests that the CTD prevents H3 binding and it may be
required to move away to allow substrate entry and efficient
catalysis. Alternatively, this might be an indication that the H3
peptide may adopt a different conformation when binding to
SmyD2. Considering the potential motion of the CTD, it is also
likely that the CTD conformation observed in the crystal
structures represents a non-physiological state of the protein.
Importantly, mutation or deletion of the CTD significantly
increased both substrate binding and H3 methylation by SmyD1,
demonstrating that this domain plays a negative role in the
regulation of the protein’s activity [18]. Together with previous
functional studies [4,18], these observations support the idea that
the histone methyltransferase activity of SmyD proteins is
regulated by autoinhibition that involves the conserved CTD.
Maintenance of SmyD2 autoinhibited conformation
SmyD2 methylates histone H3 to a very limited extent both in
vitro and in vivo [4], and extensive interactions between the CTD
and the SET domain appear to contribute to the maintenance of
the autoinhibited state of SmyD2 (Figure 3). Specifically, the
interactions involve contacts mediated by the turns connecting the
CTD helices, which form a contiguous ridge that is anchored to
the concave face of the b-sheet containing b4, b10, and b11. In
addition, the residues within the antiparallel b-hairpin between b8
and b9 appear to play a central role in the interaction with the
CTD. This hairpin protrudes deep into the middle of the concave
face of the CTD, braced by the CTD helices and forming
numerous direct interactions with aH, aL, aM, and aN. In
contrast, the equivalent hairpin in SmyD1 interacts only with the
last helix (aN) from the CTD, separated by a large crevice from
the other CTD helices. In particular, the aliphatic side chain of
Glu189 stacks with the aromatic ring of Tyr422, together with
residues Leu191, Leu379, Leu386, Met412, and Ile426 forming a
continuous hydrophobic core that stretches from the hairpin down
to the bottom of the domain interface. Of particular importance,
however, are hydrogen bonds formed between with the guanidi-
nium group of Arg390, which projects from helix aL, and two
acidic residues, Glu189 and Glu190 in the b8–b9 hairpin. A
similar interaction between the b8–b9 hairpin and the CTD was
also observed in SmyD3 but absent in SmyD1 that has an open
conformation [18,19]. Given that the b8–b9 hairpin makes
extensive contacts with the CTD, this hairpin is likely to be
important in holding the SET domain and the CTD together and
maintaining the closed conformation of the substrate binding cleft.
Additional interactions that participate in stabilizing the closed
conformation are made among the residues in the loop preceding
the post-SET domain and residues in the third and fourth helices
(aJ and aK) of the CTD (Figure 3). Specifically, Asp242 forms a
hydrogen-bond interaction with Tyr374, while Leu243 partici-
pates in a hydrophobic cluster with Val337, Leu340, Tyr370,
Figure 3. Stereo view ribbon diagram of the domain interface
of N- and C-terminal lobes. Residues are colored according to
domain in which they reside, and hydrogen bonds are indicated as red
dashed lines.
doi:10.1371/journal.pone.0021640.g003
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are well conserved in SmyD family proteins [18], suggesting that
the interactions between them may also contribute to the main-
tenance of the autoinhibited state. Interestingly, substitution of the
corresponding Asp242 or Tyr370 by alanine is able to destabilize
the autoinhibited state of SmyD1, leading to a significant increase
in both H3 binding and the enzymatic activity [18].
Intradomain and interdomain flexibility of the conserved
CTD
The intra- and interdomain bending of the CTD has been
proposed to be central to the release of the autoinhibitory effect
exerted by the CTD [19]. However, there has been no direct
evidence to support this model. Significantly, the two SmyD2
structures in complex with the cofactor analogs sinefungin and
AdoHcy differ dramatically in the conformation of the CTD
(Figure 1C). Despite that the structures of SmyD2–SFG and
SmyD2–AdoHcy are highly superimposable with RMSD of
0.36 A ˚ over 400 residues, close examination reveals that the first
two helices of the CTD (aH and aI) adopt different conformations.
These two helices bend outwards with the loop between the two
helices moving ,6A ˚ further away from the catalytic SET
domain. This motion generates a less closed conformation in the
SFG-bound SmyD2 structure and slightly tightens the cavity of the
active site in SmyD2–AdoHcy. In agreement with the conforma-
tional changes, the flexible nature of the aH and aI helices is also
indicated by their higher than average isotropic temperature
factors of 41.9 A ˚ 2 for SmyD2–AdoHcy and 39.5 A ˚ 2 for SmyD2–
SFG (Table 1). We use the program DynDom to further analyze
this domain movement [25]. Two hinge bending motion regions
are identified as containing residues 294–300 and 319–322, at
which point the aH and aI helices pivot towards the SET domain
by the rotation. The hinge axis of the rotation runs approximately
perpendicular to the axis of the CTD superhelix, intersects the
helix aH and is located 1.4 A ˚ from Ca of Arg299 and 1.3 A ˚ from
Ca of Asn300. The translation component of the screw operation
describing the domain movement is 1.5 A ˚ so that the movement is
essentially a pure domain rotation. The crystal packing constraints
appear to help to stabilize the conformational diversity of SmyD2.
The overall crystal packing is effectively identical in the SmyD2–
AdoHcy and SmyD2–sinefungin complexes, except at the packing
interfaces that involve aH and aI (Figure 4). The different
orientations of these two helices are stabilized by the differences in
crystal packing contacts that contain spatially close but distinct sets
of residues. Collectively, these findings provide the first evidence of
the intradomain flexibility of the CTD and the structural basis for
the model of the conformational changes in the CTD that
regulates the activity.
The CTD is located over 30 A ˚ distant from the cofactor and
does not contribute residues to cofactor binding. It is not apparent
from the structure how such a long-range conformational change
is triggered by the cofactors and propagated from the cofactor
binding pocket, because of the highly superimposable cofactor
binding sites and no significant structural changes in their
immediate neighboring regions. There are, however, some
differences caused by the CTD motion in the interaction networks
between the CTD and post-SET domain, including a new
hydrogen bond between the side chains of Arg299 and Glu248
and the potential salt-bridge interactions between Arg306 and
Asp256 in SmyD2–AdoHcy. Nevertheless, the long-range confor-
mational change triggered by the exchange of the cofactors could
have at least one important functional implication. Sinefungin
more resembles AdoMet than AdoHcy in structure, with the C–
NH3 amine group in place of the S–CH3 sulfonium. Our findings
may then suggest that the binding of the substrate AdoMet to
SmyD2 may partially relieve the inhibition by the CTD by causing
it to move away from the catalytic domain. The ability of the
conformation changes induced by cofactors appears to be specific
to SmyD2. Several structures of SmyD3 have been recently been
deposited in the protein data bank including SmyD3–AdoMet,
SmyD3–sinefungin, and SmyD3–AdoHcy complexes [19,26].
Despite marked differences in crystal packing, these SmyD3
complexes display essentially identical structures independent of
the types of cofactor, suggesting some differences in allosteric
properties among SmyD family members.
The exceptionally large differences in the domain-domain
orientation or with respect to the distance separating the N- and
C-terminal lobes have been observed between SmyD1 and
SmyD3 [18,19]. As a result of the differences, the CTD in
SmyD3 adopts a closed conformation that blocks the putative
H3K4 binding cleft, whereas the SmyD1 CTD displays an open
state with the active site completely exposed. Interestingly, the
SmyD2 structures display substantial differences from both
SmyD1 and SmyD3 in regard to the CTD orientation. The
differences can be viewed when the N-terminal lobes from
SmyD2, SmyD1, and SmyD3 are structurally aligned as shown
in Figure 1. In this view, the N-terminal lobe remains essentially
unchanged, but the CTDs move to either widen or narrow the
deep crevice between the N- and C-terminal lobes, essentially
mimicking how a clam shell opens and closes. In particular, the Ca
atoms of some residues near the outer edge of the CTD move as
much as 12 A ˚ between SmyD3 and SmyD1, whereas two SmyD2
structures appear to be a conformational ‘‘intermediate’’ between
the close form of SmyD3 and the open form of SmyD1. Although
the active site pocket of both SmyD2 and SmyD3 is partially
closed by the CTD that leads to steric clash with the modeled H3
peptide, significant differences are observed in the first two helices
of the CTD. The helices equivalent to aH and aI in SmyD3 form
Figure 4. Comparison of the crystal contacts of SmyD2–SFG
and SmyD2–SAH. SmyD2–SFG is depicted in red and its symmetry-
related molecule in pink. Both SmyD2–SAH molecules are colored
gray. Residues involved in crystal contacts are displayed as sticks and
colored green and cyan in SmyD2–SFG and SmyD2–SAH, respectively.
The prime symbol denotes residues and secondary structures in the
symmetry-related molecules.
doi:10.1371/journal.pone.0021640.g004
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domains [19], but the SmyD2 structures reveal that these two
helices swing outwards and maintain a narrow gap with the SET
domain on top of the active site pocket. This structural difference,
however, does not cause a significant change in the contact area
between the CTD and the rest of protein, with the total buried
surface area in the domain interface of 3766 A ˚ 2 in SmyD3
compared to 3796 A ˚ 2 and 3682 A ˚ 2 in SmyD2–AdoHcy and
SmyD2–SFG, respectively. Taken together, the differences in the
domain–domain orientation between SmyD2 and other SmyD
proteins further suggest that the CTD is able to undergo a hinge
bending-like motion, which could regulate access to the active site.
A model of SmyD2 activation by Hsp90
It has been reported that interaction between SmyD2 and
Hsp90 is important for the histone methyltransferase activity of
SmyD2, which is in agreement with results for SmyD1 and
SmyD3 [4,5,6]. The manner in which Hsp90 contributes as a
cofactor of SmyD proteins is still unclear. Given the differences in
the CTD conformations of SmyD proteins, it has been proposed
that Hsp90 activates SmyD proteins through the displacement of
the autoinhibitory effect of the CTD, which in turn leads to the
exposure of the CTD-blocked active site [19]. However, the
question regarding the mechanics of how Hsp90 causes the CTD
motion remains elusive. Hsp90 is essential for maintaining the
activity of numerous signaling proteins and it plays a key role in
cellular signal transduction networks [27]. In fulfilling its role,
Hsp90 often operates by interacting with a variety of proteins that
contain a TPR domain. At the very C-terminal end of Hsp90 is
the TPR motif recognition site, a conserved MEEVD pentapep-
tide, that is responsible for the interaction with many TPR
proteins such as the immunophilins FKBP51/52, the stress
induced phosphoprotein Hop, cyclophilin Cyp40, and a protein
phosphatase PP5 [28].
Interestingly, a search using the Dali server reveals that the
conserved CTD, which sterically blocks the substrate binding site,
resembles the structure of TPR repeats [29]. The CTD is mainly
comprised of three copies of 34-amino acid, helix-turn-helix TPR
motifs, including aH–aI, aJ–aK, and aL–aM. As shown by
superposition of the CTD of SmyD2 and the TPR2 domainofHop,
the overall configuration of these two domains are similar to each
other with RMSD of 3.9 A ˚ over 128 Ca atoms (Figure 5A). The
onlysignificantdifferenceisthefirsttwohelicesoftheCTD (aHand
aI), which have a different degree of superhelical twists. The
structural similarity of the CTD and TPR repeats leads us to
hypothesize that the CTD might interact with Hsp90 via the C-
terminal MEEVD pentapeptide of the chaperone, which may be
important for SmyD2 activation. This hypothesis is in agreement
with previous studies showing that Hsp90 interaction with SmyD2
was mediated through a region other than the MYND and SET
domains [4]. To assess potential interaction between the CTD and
Hsp90, we performed a modeling study using the structure of the
TPR2 domain of Hop in complex with a C-terminal pentapeptide
MEEVD of Hsp90 (Figure 5A). In the structure of the Hop–
MEEVD complex, the Hsp90 peptide interacts with the Hop TPR2
domain in an extended conformation, with the peptide sequence
running parallel with the helices of the TPR motifs [30]. The
peptide-protein interactions are primarily dominated by hydrogen
bonds and salt-bridges involving the carboxylated groups of acidic
residues and the C-terminus of the Hsp90 MEEVD motif
interacting with conserved arginine and lysine residues lining the
basic peptide binding channel of Hop. Despite the low sequence
identities of 16% between the CTD and the TPR2 domain, most
of the arginine, lysine and asparagine residues responsible for
Hop–Hsp90 interactions are structurally conserved in SmyD2,
including residues Arg306, Lys309, Gln345, Lys387, and Arg390.
By lining up along the concave surface of the CTD, these residues
create a continuous positively charged groove predicted for
engagement of the Hsp90 acidic C-terminal region (Figure 5B).
Thisputative MEEVD bindingsite, however, is partiallyburied and
occupied by the loop between strands b8 and b9, the region that is
involved in maintaining the autoinhibited state of the protein by
interacting with the CTD (Figure 5A). The structural similarity of
the CTD to the TPR2 domain together with the buried MEEVD
binding site may suggest a mechanism of SmyD2 activation by
Hsp90, which may resemble how PP5 is activated by Hsp90. The
crystal structure of autoinhibited PP5 reveals that the TPR domain
of PP5 engages with the catalytic channel of the phosphatase
domain, restricting access to the catalytic site [31]. This auto-
inhibited conformation of PP5 is stabilized by the C-terminal helix
that contacts a region of the Hsp90-binding groove on the TPR
domain. Hsp90 activates PP5 by disrupting TPR–phosphatase
domaininteractions,permittingsubstrateaccesstotheconstitutively
active phosphatase domain. Based on these analyses, we propose a
model of SmyD2 activation by Hsp90, in which the Hsp90
MEEVD motif could compete with the b8–b9 hairpin for binding
to theSmyD2 CTD, displacing the CTD from the substratebinding
site andcausing a conformationalchangeinthe CTD.Thismodelis
in agreement with the conformational flexibility of the CTD as
revealedbythestructuraldifferencesbetween SmyD2–AdoHcyand
SmyD2–SFG (Figure 1). Additional research is required to support
this proposed mechanism and to determine whether Hsp90
interacts with the SmyD2 via the CTD and induces a conforma-
tional change in this domain.
Materials and Methods
Protein Preparation
Protein purification was performed essentially as described
previously [18]. Briefly, mouse SmyD2 was cloned into the
Figure 5. TPR-like CTD. (A) Superposition of the CTD of SmyD2–SFG
(red) and the TPR2 domain of Hop (sky blue) (PDB code 1ELR). The
Hsp90 MEEVD peptide in complex with the Hop TPR2 domain is
displayed as balls-and-sticks with carbon atoms colored yellow. (B)
Model of the Hsp90 MEEVD peptide bound in the SmyD2 CTD. The CTD
is represented by molecular surface with color coding according to the
electrostatic potential: red, white, and blue correspond to negative,
neutral, and positive potential, respectively, whereas the peptide is
shown as balls-and-sticks. Positively charged residues predicted to be
essential for peptide binding are labeled.
doi:10.1371/journal.pone.0021640.g005
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tag. Recombinant SmyD2 was then transformed into Escherichia
coli for protein expression. The transformants were grown to an
OD600 (optical density at 600 nm) of 0.4 at 37uCi n2LL B
medium, and then induced with 0.1 mM isopropylthio-b-D-
galactoside at 15uC overnight. The cells were harvested, and lysed
by French Press. The soluble fraction was then subjected to a series
of chromatography purification by an AKTA purifier system (GE
healthcare), and His6-SUMO tag was cleaved off with yeast
SUMO Protease 1. SmyD2 proteins were finally purified to
apparent homogeneity and concentrated to 10–20 mg/ml in
20 mM Tris–HCl (pH 8.0), 150 mM NaCl, 1 mM b-mercapto-
ethanol, and 5% glycerol.
Crystallization and data collection
Prior to crystallization, SmyD2 (10 mg/ml) was incubated with
2 mM AdoHcy or sinefungin at 4uC for 2 h. The binary complex
of SmyD2–AdoHcy or SmyD2–sinefungin was then crystallized by
hanging drop vapor diffusion at 20uC, with 15% polyethylene
glycol 8000, 50 mM NaCl, 100 mM Tris, pH 8.0. Crystals
typically appeared within 1 day, achieved their full size in a week.
X-ray diffraction data from single crystals were collected at
beamline 21IDD at the Advanced Photon Source (Argonne, IL)
and were then processed and scaled using the program HKL2000
[32]. The crystals belong to the orthorhombic space group
P212121 and contain one molecule in the asymmetric unit
(Table 1).
Structure determination and refinement
The crystal structure of SmyD2 in complex with AdoHcy was
solved by the single-wavelength anomalous diffraction (SAD)
method using three intrinsic zinc ions. Initial phases were obtained
using the program SOLVE [33], which was able to identify all
three zinc sites with a figure of merit of 0.329 in the resolution
range 20–2.1 A ˚. After density modification with the program
RESOLVE [33], the resulting electron density map is interpret-
able. With the modified phases, automated model building was
carried out by RESOLVE, which built 80% of the protein residues
including side chains. The model was then completed and
improved by alternating cycles of manual model building and
refinement using COOT [34] and BUSTER [35]. The final
refined model is well ordered with the exception of the first two
residues and the last residue. Because of isomorphism of crystals
(Table 1), the crystal structure of SmyD2 in complex with
sinefungin was solved by rigid-body fitting of the SmyD22A-
doHcy model followed by manual model building and refinement
as described above. The final models were analyzed and validated
with PROCHECK [36]. All figures of 3D representations of the
SmyD2 structures were made with PyMOL (www.pymol.org).
Protein Data Bank accession number
Coordinates and structure factors have been deposited in the
Protein Data Bank with accession number 3QWV and 3QWW for
SmyD22AdoHcy and SmyD22SFG, respectively.
Author Contributions
Conceived and designed the experiments: YJ NS. Performed the
experiments: YJ NS. Analyzed the data: YJ NS JB ZY. Contributed
reagents/materials/analysis tools: YJ NS JB. Wrote the paper: ZY YJ.
References
1. Berger SL (2007) The complex language of chromatin regulation during
transcription. Nature 447: 407–412.
2. Brown MA, Sims RJ, Gottlieb PD, Tucker PW (2006) Identification and
characterization of Smyd2: a split SET/MYND domain-containing histone H3
lysine 36-specific methyltransferase that interacts with the Sin3 histone
deacetylase complex. Mol Cancer 5: 26.
3. Gottlieb PD, Pierce SA, Sims RJ, Yamagishi H, Weihe EK, et al. (2002) Bop
encodes a muscle-restricted protein containing MYND and SET domains and is
essential for cardiac differentiation and morphogenesis. Nat Genet 31: 25–32.
4. Abu-Farha M, Lambert JP, Al-Madhoun AS, Elisma F, Skerjanc IS, et al. (2008)
The tale of two domains: proteomics and genomics analysis of SMYD2, a new
histone methyltransferase. Mol Cell Proteomics 7: 560–572.
5. Tan X, Rotllant J, Li H, De Deyne P, Du SJ (2006) SmyD1, a histone
methyltransferase, is required for myofibril organization and muscle contraction
in zebrafish embryos. PNAS 103: 2713–2718.
6. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, et al. (2004) SMYD3
encodes a histone methyltransferase involved in the proliferation of cancer cells.
Nat Cell Biol 6: 731–740.
7. Liu Y, Chen W, Gaudet J, Cheney MD, Roudaia L, et al. (2007) Structural basis
for recognition of SMRT/N-CoR by the MYND domain and its contribution to
AML1/ETO’s activity. Cancer Cell 11: 483–497.
8. Li D, Niu Z, Yu W, Qian Y, Wang Q, et al. (2009) SMYD1, the myogenic
activator, is a direct target of serum response factor and myogenin. Nucleic Acids
Res 37: 7059–7071.
9. Kawamura S, Yoshigai E, Kuhara S, Tashiro K (2008) smyd1 and smyd2 are
expressed in muscle tissue in Xenopus laevis. Cytotechnology 57: 161–168.
10. Diehl F, Brown MA, van Amerongen MJ, Novoyatleva T, Wietelmann A, et al.
(2010) Cardiac deletion of Smyd2 is dispensable for mouse heart development.
PLoS One 5: e9748.
11. Thompson EC, Travers AA (2008) A Drosophila Smyd4 homologue is a muscle-
specific transcriptional modulator involved in development. PLoS One 3: e3008.
12. Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, et al. (2006)
Repression of p53 activity by Smyd2-mediated methylation. Nature 444:
629–632.
13. Saddic LA, West LE, Aslanian A, Yates JR, Rubin SM, et al. (2010) Methylation
of the retinoblastoma tumor suppressor by SMYD2. J Biol Chem 24: 24.
14. Komatsu S, Imoto I, Tsuda H, Kozaki KI, Muramatsu T, et al. (2009)
Overexpression of SMYD2 relates to tumor cell proliferation and malignant
outcome of esophageal squamous cell carcinoma. Carcinogenesis 30:
1139–1146.
15. Soti C, Racz A, Csermely P (2002) A Nucleotide-dependent molecular switch
controls ATP binding at the C-terminal domain of Hsp90. N-terminal
nucleotide binding unmasks a C-terminal binding pocket. J Biol Chem 277:
7066–7075.
16. Tariq M, Nussbaumer U, Chen Y, Beisel C, Paro R (2009) Trithorax requires
Hsp90 for maintenance of active chromatin at sites of gene expression. Proc Natl
Acad Sci U S A 106: 1157–1162.
17. Ruden DM, Lu X (2008) Hsp90 affecting chromatin remodeling might explain
transgenerational epigenetic inheritance in Drosophila. Curr Genomics 9:
500–508.
18. Sirinupong N, Brunzelle J, Ye J, Pirzada A, Nico L, et al. (2010) Crystal structure
of cardiac-specific histone methyltransferase SmyD1 reveals unusual active site
architecture. J Biol Chem 285: 40635–40644.
19. Sirinupong N, Brunzelle J, Doko E, Yang Z (2011) Structural insights into the
autoinhibition and posttranslational activation of histone methyltransferase
SmyD3. J Mol Biol 406: 149–159.
20. Couture JF, Collazo E, Brunzelle JS, Trievel RC (2005) Structural and
functional analysis of SET8, a histone H4 Lys-20 methyltransferase. Genes Dev
19: 1455.
21. Wilson JR, Jing C, Walker PA, Martin SR, Howell SA, et al. (2002) Crystal
structure and functional analysis of the histone methyltransferase SET7/9. Cell
111: 105–115.
22. Zhang X, Tamaru H, Khan SI, Horton JR, Keefe LJ, et al. (2002) Structure of
the Neurospora SET domain protein DIM-5, a histone H3 lysine methyltrans-
ferase. Cell 111: 117.
23. Couture JF, Collazo E, Hauk G, Trievel RC (2006) Structural basis for the
methylation site specificity of SET7/9. Nat Struct Mol Biol 13: 140–146.
24. Zhang X, Yang Z, Khan SI, Horton JR, Tamaru H, et al. (2003) Structural basis
for the product specificity of histone lysine methyltransferases. Mol Cell 12:
177–185.
25. Hayward S, Berendsen HJ (1998) Systematic analysis of domain motions in
proteins from conformational change: new results on citrate synthase and T4
lysozyme. Proteins 30: 144–154.
26. Xu S, Wu J, Sun B, Zhong C, Ding J (2011) Structural and biochemical studies
of human lysine methyltransferase Smyd3 reveal the important functional roles
of its post-SET and TPR domains and the regulation of its activity by DNA
binding. Nucleic Acids Res 25: 25.
27. Pearl LH, Prodromou C (2000) Structure and in vivo function of Hsp90. Curr
Opin Struct Biol 10: 46–51.
Crystal Structures of SmyD2
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e2164028. Young JC, Obermann WM, Hartl FU (1998) Specific binding of tetratricopep-
tide repeat proteins to the C-terminal 12-kDa domain of hsp90. J Biol Chem
273: 18007–18010.
29. Holm L, Rosenstrom P (2010) Dali server: conservation mapping in 3D. Nucleic
Acids Res 38: W545–549.
30. Scheufler C, Brinker A, Bourenkov G, Pegoraro S, Moroder L, et al. (2000)
Structure of TPR domain-peptide complexes: critical elements in the assembly
of the Hsp70-Hsp90 multichaperone machine. Cell 101: 199–210.
31. Yang J, Roe SM, Cliff MJ, Williams MA, Ladbury JE, et al. (2005) Molecular
basis for TPR domain-mediated regulation of protein phosphatase 5. Embo J 24:
1–10.
32. Otwinowski Z, Minor W (1997) Processing of X-ray Diffraction Data Collected
in Oscillation Mode. Methods in Enzymology 276: 307–326.
33. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, et al.
(2002) PHENIX: building new software for automated crystallographic structure
determination. Acta Crystallogr D Biol Crystallogr 58: 1948–1954.
34. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics.
Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
35. Blanc E, Roversi P, Vonrhein C, Flensburg C, Lea SM, et al. (2004) Refinement
of severely incomplete structures with maximum likelihood in BUSTER-TNT.
Acta Crystallogr D Biol Crystallogr 60: 2210–2221.
36. Laskowski RA, MacArthur MW, Moss DS, Thornton JM (1993) PROCHECK:
A program to check the stereochemical quality of protein structures. J Appl
Cryst 26: 283–291.
Crystal Structures of SmyD2
PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e21640